Literature DB >> 15960554

Bipolar disorder and health-related quality of life : review of burden of disease and clinical trials.

Dennis A Revicki1, Louis S Matza, Emuella Flood, Andrew Lloyd.   

Abstract

Bipolar disorder is a chronic psychiatric disorder with a variable course and significant impact on patients' social, occupational, and general functioning and wellbeing. Although there are effective pharmaceutical and psychosocial interventions for patients with bipolar disorder, many patients receive poor-quality care. Prospective longitudinal studies demonstrate that less than half of bipolar disorder patients have a good long-term response to treatment, long-term outcome is highly variable, and many patients do not fully recover. There is substantial evidence that bipolar disorder is associated with significant impairment to functioning and wellbeing.However, few clinical trials comparing treatments for bipolar disorder have incorporated health-related quality-of-life (HR-QOL) assessments. Existing studies suggest that, while treatment improves HR-QOL, there is limited evidence for differences between the mood stabilisers in terms of HR-QOL outcomes. Additional clinical trials are needed to evaluate patient-reported outcomes associated with the most frequently used pharmacological treatments to determine whether there are meaningful differences between treatments. There are challenges in measuring HR-QOL in patients with acute mania, and future studies should assess the psychometric qualities of HR-QOL instruments in these and other bipolar disorder patients. HR-QOL outcome data may be useful in informing psychiatrists, patients and patient family members of the effects of treatment for bipolar disorder on patients' everyday lives, functioning and wellbeing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15960554     DOI: 10.2165/00019053-200523060-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  63 in total

1.  Psychometric assessment of the Quality of Life Index.

Authors:  C E Ferrans; M J Powers
Journal:  Res Nurs Health       Date:  1992-02       Impact factor: 2.228

2.  A double-blind comparison of valproate and lithium in the treatment of acute mania.

Authors:  T W Freeman; J L Clothier; P Pazzaglia; M D Lesem; A C Swann
Journal:  Am J Psychiatry       Date:  1992-01       Impact factor: 18.112

3.  Health care utilization and costs among patients treated for bipolar disorder in an insured population.

Authors:  G E Simon; J Unützer
Journal:  Psychiatr Serv       Date:  1999-10       Impact factor: 3.084

4.  Levels of functioning and well-being in recovered psychotic versus nonpsychotic mania.

Authors:  G M MacQueen; L T Young; J C Robb; R G Cooke; R T Joffe
Journal:  J Affect Disord       Date:  1997-10       Impact factor: 4.839

5.  Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

Authors:  M Tohen; T G Jacobs; S L Grundy; S L McElroy; M C Banov; P G Janicak; T Sanger; R Risser; F Zhang; V Toma; J Francis; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-09

6.  Self-reported quality of life across mood states in bipolar disorder.

Authors:  C Vojta; B Kinosian; H Glick; L Altshuler; M S Bauer
Journal:  Compr Psychiatry       Date:  2001 May-Jun       Impact factor: 3.735

7.  Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes.

Authors:  Dennis A Revicki; L Clark Paramore; Kenneth W Sommerville; Alan C Swann; John M Zajecka
Journal:  J Clin Psychiatry       Date:  2003-03       Impact factor: 4.384

8.  Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.

Authors:  J Endicott; J Nee; W Harrison; R Blumenthal
Journal:  Psychopharmacol Bull       Date:  1993

9.  Quality of life and lifestyle disruption in euthymic bipolar disorder.

Authors:  J C Robb; R G Cooke; G M Devins; L T Young; R T Joffe
Journal:  J Psychiatr Res       Date:  1997 Sep-Oct       Impact factor: 4.791

10.  Symptoms and functioning of patients with bipolar disorder six months after hospitalization.

Authors:  G L Dion; M Tohen; W A Anthony; C S Waternaux
Journal:  Hosp Community Psychiatry       Date:  1988-06
View more
  22 in total

1.  Metabolic syndrome in Tunisian bipolar I patients.

Authors:  A Ezzaher; Mouhamed D Haj; A Mechri; F Neffati; W Douki; L Gaha; M F Najjar
Journal:  Afr Health Sci       Date:  2011-09       Impact factor: 0.927

2.  Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.

Authors:  Tatia Chay Woodward; Eskinder Tafesse; Peter Quon; Arthur Lazarus
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  An Integrated Risk Reduction Intervention can reduce body mass index in individuals being treated for bipolar I disorder: results from a randomized trial.

Authors:  Ellen Frank; Meredith L Wallace; Martica Hall; Brant Hasler; Jessica C Levenson; Carol A Janney; Isabella Soreca; Matthew C Fleming; Joan Buttenfield; Fiona C Ritchey; David J Kupfer
Journal:  Bipolar Disord       Date:  2014-12-12       Impact factor: 6.744

4.  Are adults with bipolar disorder active? Objectively measured physical activity and sedentary behavior using accelerometry.

Authors:  Carol A Janney; Andrea Fagiolini; Holly A Swartz; John M Jakicic; Robert G Holleman; Caroline R Richardson
Journal:  J Affect Disord       Date:  2013-09-18       Impact factor: 4.839

5.  BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments.

Authors:  Sungho Maeng; Joshua G Hunsberger; Brandon Pearson; Peixiong Yuan; Yun Wang; Yanling Wei; Joseph McCammon; Robert J Schloesser; Rulun Zhou; Jing Du; Guang Chen; Bruce McEwen; John C Reed; Husseini K Manji
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

Review 6.  Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets.

Authors:  Paul J Carlson; Jaskaran B Singh; Carlos A Zarate; Wayne C Drevets; Husseini K Manji
Journal:  NeuroRx       Date:  2006-01

Review 7.  Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression.

Authors:  Emma D Deeks; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Intracerebral Administration of BDNF Protects Rat Brain Against Oxidative Stress Induced by Ouabain in an Animal Model of Mania.

Authors:  Samira S Valvassori; Camila O Arent; Amanda V Steckert; Roger B Varela; Luciano K Jornada; Paula T Tonin; Josiane Budni; Edemilson Mariot; Flávio Kapczinski; João Quevedo
Journal:  Mol Neurobiol       Date:  2014-08-28       Impact factor: 5.590

Review 9.  Asenapine.

Authors:  Juliane Weber; Paul L McCormack
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

10.  Review of olanzapine in the management of bipolar disorders.

Authors:  Meera Narasimhan; Travis O Bruce; Prakash Masand
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.